title: Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories.
abstract: Standardization of the hemagglutination inhibition (HAI) assay for influenza serology is challenging. Poor reproducibility of HAI results from one laboratory to another is widely cited, limiting comparisons between candidate vaccines in different clinical trials and posing challenges for licensing authorities. In this study, we standardized HAI assay materials, methods, and interpretive criteria across five geographically dispersed laboratories of a multidisciplinary influenza research network and then evaluated intralaboratory and interlaboratory variations in HAI titers by repeatedly testing standardized panels of human serum samples. Duplicate precision and reproducibility from comparisons between assays within laboratories were 99.8% (99.2% to 100%) and 98.0% (93.3% to 100%), respectively. The results for 98.9% (95% to 100%) of the samples were within 2-fold of all-laboratory consensus titers, and the results for 94.3% (85% to 100%) of the samples were within 2-fold of our reference laboratory data. Low-titer samples showed the greatest variability in comparisons between assays and between sites. Classification of seroprotection (titer ≥ 40) was accurate in 93.6% or 89.5% of cases in comparison to the consensus or reference laboratory classification, respectively. This study showed that with carefully chosen standardization processes, high reproducibility of HAI results between laboratories is indeed achievable.
authors.affiliation: Research Institute of the McGill University Health Centre, Montreal, QC, Canada BioZac Consulting, Pointe Claire, QC, Canada.
authors.forename: Mary
authors.initials: M
authors.lastname: Zacour
authors.affiliation: Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
authors.forename: Brian J
authors.initials: BJ
authors.lastname: Ward
authors.affiliation: Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
authors.forename: Angela
authors.initials: A
authors.lastname: Brewer
authors.affiliation: British Columbia Centre for Disease Control, Vancouver, BC, Canada.
authors.forename: Patrick
authors.initials: P
authors.lastname: Tang
authors.affiliation: CHU de Quebec and Laval University, Quebec City, QC, Canada.
authors.forename: Guy
authors.initials: G
authors.lastname: Boivin
authors.affiliation: National Microbiology Laboratory, Winnipeg, MB, Canada.
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.affiliation: Canadian Center for Vaccinology, Dalhousie, Halifax, NS, Canada.
authors.forename: Michelle
authors.initials: M
authors.lastname: Warhuus
authors.affiliation: Canadian Center for Vaccinology, Dalhousie, Halifax, NS, Canada Department of Medicine, Nova Scotia Health Authority, Halifax, NS, Canada.
authors.forename: Shelly A
authors.initials: SA
authors.lastname: McNeil
authors.affiliation: Canadian Center for Vaccinology, Dalhousie, Halifax, NS, Canada Department of Pathology and Laboratory Medicine, Nova Scotia Health Authority, Halifax, NS, Canada.
authors.forename: Jason J
authors.initials: JJ
authors.lastname: LeBlanc
authors.affiliation: Canadian Center for Vaccinology, Dalhousie, Halifax, NS, Canada Department of Medicine, Nova Scotia Health Authority, Halifax, NS, Canada Department of Pathology and Laboratory Medicine, Nova Scotia Health Authority, Halifax, NS, Canada todd.hatchette@cdha.nshealth.ca.
authors.forename: Todd F
authors.initials: TF
authors.lastname: Hatchette
mesh_terms: D000914:Antibodies, Viral / Q000097:blood*; D006385:Hemagglutination Inhibition Tests / Q000379:methods*; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D053122:Influenza A Virus, H3N2 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology*; D015203:Reproducibility of Results
chemical_list: D000914:Antibodies, Viral; D007252:Influenza Vaccines
references.citation: CMAJ. 2010 Nov 23;182(17):1851-6
references.pmid: 20956500
references.citation: Vaccine. 2010 Apr 26;28(19):3416-22
references.pmid: 20206285
references.citation: Emerg Infect Dis. 2009 Aug;15(8):1252-9
references.pmid: 19751587
references.citation: Clin Vaccine Immunol. 2009 Apr;16(4):558-66
references.pmid: 19225073
references.citation: Pharm Res. 2007 Oct;24(10):1962-73
references.pmid: 17458684
references.citation: Vaccine. 2007 May 16;25(20):4056-63
references.pmid: 17412461
references.citation: Vaccine. 1994 Feb;12(2):167-74
references.pmid: 8147099
references.citation: Dev Biol (Basel). 2003;115:63-73
references.pmid: 15088777
references.citation: Pharm Res. 2003 Nov;20(11):1885-900
references.pmid: 14661937
references.citation: J Pharm Biomed Anal. 2000 Jan;21(6):1249-73
references.pmid: 10708409
references.citation: J Infect Dis. 2015 Aug 15;212(4):562-9
references.pmid: 25712969
references.citation: Euro Surveill. 2014;19(1). pii: 20668
references.pmid: 24434176
references.citation: Clin Vaccine Immunol. 2015 Aug;22(8):957-64
references.pmid: 26108286
references.citation: Pharmeur Bio Sci Notes. 2011 Jun;2011(1):27-35
references.pmid: 21619854
references.citation: Pharmeur Bio Sci Notes. 2011 Jun;2011(1):36-54
references.pmid: 21619855
references.citation: Vaccine. 2011 Oct 13;29(44):7579-86
references.pmid: 21856358
references.citation: Pediatr Infect Dis J. 2011 Dec;30(12):1081-5
references.pmid: 21983214
references.citation: Vaccine. 2012 Jan 5;30(2):210-7
references.pmid: 22100887
references.citation: Vaccine. 2012 Jun 8;30(27):4113-22
references.pmid: 22446639
references.citation: J Clin Virol. 2013 Apr;56(4):323-30
references.pmid: 23375739
references.citation: Influenza Other Respir Viruses. 2013 May;7(3):231-4
references.pmid: 23280042
references.citation: Expert Rev Vaccines. 2013 May;12(5):519-36
references.pmid: 23659300